Natalizumab (NAT) is a highly efficacious treatment for relapsing-remitting MS (RRMS) and hinders immune cells from entry into the CNS. However, this also compromises physiologic CNS immune surveillance and is an important reason for NAT-associated progressive multifocal leukoencephalopathy (NAT-PML). PML is an opportunistic CNS infection with JC polyomavirus (JCV) and has emerged as a serious adverse event in 778 NAT-treated patients worldwide (incidence of 4.2/1,000) with fatal outcome in 23% of cases,^[@R1],[@R2]^ whereas other CNS infections occur far less frequently (incidence of herpes virus CNS infections at 0.2/1,000).^[@R3]^ Why NAT-treated patients are more prone to develop PML than other viral CNS infections is not clear.^[@R4]^

NAT impairs entry of B and plasma cells into the CNS and is associated with decreased total CSF IgG and IgM levels.^[@R5][@R6][@R7]^ Moreover, NAT may reduce the prevalence, number, and/or intensity of CSF oligoclonal bands (OCBs),^[@R7][@R8][@R9]^ whereas the influence on polyspecific intrathecal antibody reactivity to measles, rubella, and zoster (MRZ reaction) remains less examined.^[@R7]^ Positive OCBs and MRZ reaction in CSF are common, well established, and stable surrogates of ongoing intrathecal humoral immune reaction in MS.^[@R10],[@R11]^ Intrathecal production of JCV-specific antibodies has been described in 3.6% of patients with MS^[@R12]^ and thus may be part of the "polyspecific" CSF humoral immune reaction, which is usually depicted by the MRZ reaction, but which extends to many other viruses.^[@R12][@R13][@R15]^ Of interest, JCV-specific CSF antibody production was not found in NAT-treated patients with MS, but in 55% of patients with NAT-PML,^[@R16]^ indicating that it is an important aspect of protective immune responses against PML.

Here, we addressed how NAT influences the spectrum of intrathecally produced antibodies against various pathogens including JCV.

Methods {#s1}
=======

Patients and samples {#s1-1}
--------------------

Paired serum and CSF samples were collected from 15 patients (male/female ratio 1:4; mean age 40.13 years \[range 18--53 years\]) diagnosed with RRMS according to 2005 revised McDonald criteria^[@R17]^ at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, before NAT (V0), and after 12 months (V12) and 24 months (V24, only from 6 patients, loss of follow-up in 9 patients due to denial of further participation) of NAT treatment (300 mg IV every 4 weeks). The patients had not received steroids 4 weeks before NAT treatment or any immunomodulatory or immunosuppressive agent 3 months before NAT treatment. Additional 25 serum samples from healthy donors were used for determining the cutoff value (COV) of seropositivity in JCV ELISA.

Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

The local ethics committee (Ethik-Kommission der Ärztekammer Hamburg, Germany, protocol No. 2758) approved the study. All patients gave written informed consent.

Antibody detection in serum and CSF {#s1-3}
-----------------------------------

Antibody reactivity against the following viral lysates and bacterial antigens was tested using commercial ELISA kits from Euroimmun (Lübeck, Germany): measles, rubella, mumps, herpes simplex virus type 1/2 (HSV-1/HSV-2), cytomegalovirus (CMV), varicella zoster virus (VZV), influenza virus A and B (influenza A and B), and enterovirus lysates; Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) and EBV viral capsid antigen (EBV-VCA); and tetanus toxoid (tetanus), diphtheria toxoid (diphtheria), *Helicobacter pylori*, and *Chlamydophila pneumoniae* antigens. Antipolyomaviral IgG reactivity was determined using BK polyomavirus (BKV)-, KI polyomavirus (KIV)-, or WU polyomavirus (WUV)-viral protein 1 (VP1) fused to glutathione S-transferase (kind gift from Robert L. Garcea, Boulder, CO) or JCV-VP1 (MAD1 strain, Life Science Incubator, Bonn, Germany), as described previously.^[@R18],[@R19]^ Briefly, ELISA plates were coated with 200 ng of the respective polyomavirus-VP1/well and incubated with serum (1:400, 1:2,020 dilutions) and CSF (1:2, 1:10, 1:100, and 1:1,000 dilutions). Human IgG was detected using biotin-conjugated anti-human mouse Fc antibody and avidin horseradish peroxidase (eBioscience, Frankfurt, Germany). Optical density at 450 nm (OD~450~) was assessed using a Synergy H1 reader (BioTek, Luzern, Switzerland). Antibody reactivity was assessed in arbitrary units (AUs) using a standard curve obtained from a serial dilution of the respective standard serum for interpolating ODs by 4 parameter logistic curve fit. AUs within the linear part of the standard curve were multiplied by the corresponding dilution factor to obtain absolute AU. Highly reactive samples exceeding the linear limits of the standard curve were further diluted.

The antigen-specific CSF/serum antibody index (CAI~spec~) was calculated according to Reiber.^[@R20]^ Briefly, CAI~spec~ was assessed as CAI~spec~ = Q~spec~/Q~IgG~, if Q~Lim~ \> Q~IgG~, or CAI = Q~spec~/Q~Lim~ (IgG), if Q~Lim~ \< Q~IgG~. The variables were calculated as follows: Q~spec~ = antigen-specific IgG~CSF~ \[AU\]/antigen-specific IgG~serum~ \[AU\]; Q~IgG~ = IgG~CSF~/IgG~serum~; Q~Lim~ (IgG) = 0.93× (Q~alb~^2^ + 6 × 10^−6^)^0.5^ − 1.7 × 10^−3^; Q~alb~ = alb~CSF~/alb~serum~ (with alb = albumin). Q~Lim~ (IgG) refers to the upper discrimination line of the hyperbolic reference range for the blood-derived IgG in CSF as 0 intrathecal IgG synthesis. Intrathecal antigen-specific antibody synthesis was defined as CAI~spec~ ≥ 1.5. Serum and CSF samples were preincubated with BKV before testing with JCV ELISA and vice versa to assess JCV/BKV cross-reactivity. For the determination of the COV of JCV, BKV, KIV, and WUV seropositivity, we measured sera from the above-mentioned patients with MS and additional 25 healthy donors (among them seropositive and negative donors) using antigen-specific ELISA. Normalized ODs were calculated by subtracting the mean OD of negative controls and divided by the OD of 1/500 diluted standard serum. We determined the COV of antigen-specific seropositivity by ranking normalized ODs and calculating the inflection point.

Albumin and total IgG, IgM, and IgA in serum and CSF were quantified by immunonephelometry (Unilabs, Zurich, Switzerland). IgG index was calculated as IgG index = Q~IgG~/Q~alb~ (for Q~IgG~ and Q~alb~ see above) and IgM index and IgA index each accordingly. IgG index ≥0.7 indicated intrathecal synthesis of IgG. The relative intrathecal fraction of IgM and IgA, respectively (IgM~IF~ and IgA~IF~), were calculated according to Reiber.^[@R20]^ IgM~IF~ ≥ 10% and IgA~IF~ ≥ 10% indicated significant intrathecal synthesis of IgM and IgA, respectively. OCBs were detected by isoelectric focusing on polyacrylamide gels and immunoblotting using IgG-specific antibodies (Serva, Germany, Heidelberg, Germany). OCBs were considered positive in case of ≥2 additional bands.

Statistical analysis {#s1-4}
--------------------

Prism v5.0 (GraphPad software, San Diego, CA) was used for statistical analysis. The McNemar test (for dichotomous measures) and Wilcoxon-matched pairs test (for quantitative measures) were used to compare between V0 and V12. To test whether the frequency of loss of intrathecal antibody synthesis specific for a given antigen between V0 and V12 is the same as the frequency of loss of intrathecal antibody synthesis specific for all other antigens between V0 and V12, we used the Fisher exact test. All the 20 antigens tested and recognized by intrathecally produced antibodies were regarded as a priori independent of each other. The primary aim was to compare whether loss of intrathecal JCV-specific antibody synthesis between V0 and V12 was significantly more frequent than the loss of intrathecal antibody synthesis specific for all antigens other than JCV. Probability values of *p* \< 0.05 were considered significant in the primary aim. A second, exploratory aim was to compare the frequency of loss of intrathecal antibody synthesis specific for the following respective antigen between V0 and V12 against that for all other respective antigens: (1) JCV against all other antigens, (2) BKV, (3) KIV, (4) WUV, (5) measles, (6) rubella, (7) VZV, (8) mumps, (9) HSV-1, (10) HSV-2, (11) CMV, (12) EBV-VCA, (13) EBNA-1, (14) influenza A, (15) influenza B, (16) enterovirus, (17) tetanus, (18) diphtheria, (19) *H pylori*, (20) *C pneumoniae*, (21) JCV or BKV, and (22) positive MRZ reaction. In this exploratory aim, probability values of *p* \< 0.00227 (0.05/22) were considered significant according to Bonferroni correction for multiple comparisons.

Data availability {#s1-5}
-----------------

Anonymized data will be shared upon request by qualified investigators.

Results {#s2}
=======

Changes of total immunoglobulin levels in serum and CSF during NAT therapy {#s2-1}
--------------------------------------------------------------------------

We first analyzed total IgG, IgM, and IgA levels in serum ([figure 1, A--C](#F1){ref-type="fig"}) and CSF ([figure 1, D--F](#F1){ref-type="fig"}) and intrathecal production of total IgG, IgM, and IgA ([figure 1G--L](#F1){ref-type="fig"}) in 15 patients with RRMS (male/female ratio 1:4; mean age 40.13 years \[range 18--53 years\]) before (V0) and during NAT treatment (V12). Total IgG levels in CSF and intrathecal production of total IgG, as determined by IgG index, decreased significantly during NAT therapy ([figure 1D, G, and J](#F1){ref-type="fig"}). In addition, NAT treatment significantly reduced total IgM levels in serum and CSF, intrathecal production of IgM (IgM index), and total IgA levels in CSF ([figure 1B, E, F, and H](#F1){ref-type="fig"}). However, the prevalence of donors showing intrathecal IgG, IgM, or IgA production, i.e., IgG index ≥0.7, or local IgM or IgA production ≥10%, did not change significantly during NAT therapy ([figure 1J--L](#F1){ref-type="fig"}).

![Total IgG, IgM, and IgA in the CSF and serum of patients with MS before and during NAT treatment\
Changes of absolute levels of total IgG, IgM, and IgA in serum (A--C) and CSF (D--F) during NAT therapy are shown. Changes in intrathecal production of total IgG, IgM, and IgA are shown by depicting IgG, IgM, and IgA index (ratio of CSF/serum antibodies normalized to ratio CSF/serum albumin) (G--I), as well as prevalence of patients with significant intrathecal synthesis of IgG, IgM, or IgA (J--L), respectively, as indicated by IgG index ≥0.7, IgM~IF~ ≥10%, and IgA~IF~ ≥10%, respectively, before (V0) and after 12 months (V12) of NAT treatment (n = 15). The *p* value is shown in case of statistically significant differences. Statistics: Wilcoxon-matched pairs test (A--I) and McNemar test (J--L). NAT = natalizumab.](NEURIMMINFL2018018242FF1){#F1}

Heterogeneity of intrathecal production of pathogen-specific antibodies in untreated patients with MS {#s2-2}
-----------------------------------------------------------------------------------------------------

To assess the influence of NAT therapy on antigen-specific IgG responses, we analyzed serum and CSF levels, as well as intrathecal production of antigen-specific antibodies, i.e., antigen-specific CAI~antigen~, at before treatment (V0; n = 15), after 12 months (V12; n = 15), and after 24 months of NAT treatment (V24; n = 6: MS01--MS06) using an array of 20 viral and bacterial antigens ([figure 2](#F2){ref-type="fig"}). The prevalence of donors seropositive for the respective antigens was comparable with data from the literature and did not change during NAT therapy (figure e-1, [links.lww.com/NXI/A146](http://links.lww.com/NXI/A146)). As expected, the spectrum of antigens recognized by intrathecally produced IgG varied considerably among therapy-naive individuals (V0, [figures 2 and 3A](#F2 F3){ref-type="fig"}). Before NAT therapy, intrathecal production of antibodies against ≥1 antigen was detectable in 86.7% of donors, against ≥2 antigens in 80.0% of donors ([figures 2 and 3B](#F2 F3){ref-type="fig"}). No intrathecal production of antibodies reactive to any of the 20 antigens tested was observed in 2 donors (13.3%, MS06 and MS15 at V0 in [figure 2](#F2){ref-type="fig"}), whereas intrathecal production of antibodies against 10 antigens was found in 2 other donors (MS01 and MS07 at V0 in [figure 2](#F2){ref-type="fig"}). The antigens most frequently recognized by intrathecally produced antibodies were measles (73.3% of donors), rubella (60.0%), and VZV (53.3%), followed by influenza B virus (46.7%) and *C pneumoniae* (40.0%) ([figure 3A](#F3){ref-type="fig"}). MRZ reaction, defined as polyclonal intrathecal antibody reactivity to ≥2 of the 3 antigens measles (M), rubella (R), and zoster (Z), was positive in 73.3% ([figure 3B](#F3){ref-type="fig"}), consistent with the proportion reported in the literature.^[@R10],[@R21]^ Intrathecal synthesis of antibodies against mumps virus (33.3%), tetanus toxoid (33.3%), influenza A virus (26.7%), HSV-1 (20.0%), HSV-2 (6.7%), CMV (6.7%), and enterovirus (6.7%) was less frequent. No intrathecal synthesis of antibodies reactive against EBV-VCA, EBNA-1, diphtheria toxoid, or *H pylori* was detectable ([figures 2 and 3A](#F2 F3){ref-type="fig"}). Of interest, intrathecal antibody synthesis to the polyomaviruses, KIV (26.7%), JCV (20.0%), BKV (20.0%), and WUV (13.3%), was detected in some therapy-naive patients.

![Antigen spectrum recognized by intrathecally produced antibodies in patients with MS before and during NAT treatment.\
Antigens are divided into polyomaviral VP1 (PyV: JCV, BKV, KIV, and WUV), viral lysates of the MRZ reaction (measles \[M\], rubella \[R\], and VZV \[Z\]), lysates or antigens from other neurotropic viruses (mumps, HSV-1, HSV-2, CMV, EBV-VCA, EBNA-1, influenza A, influenza B, and enterovirus), toxoids (tetanus and diphtheria toxoids), and bacterial antigens (from non-neurotropic *H pylori* and from neurotropic *C pneumoniae*). Black indicates intrathecal antibody synthesis (CAI ≥ 1.5), and white no antigen-specific intrathecal antibody synthesis (CAI \< 1.5). Samples with AUs below 5 were considered as not detectable (N). Longitudinal samples of patients with MS were available from before treatment (V0; n = 15), after 12 months (V12; n = 15), and after 24 months of NAT treatment (V24; n = 6: only MS01--MS06). Detection of OCBs in the corresponding serum and CSF samples and/or additional bands in CSF is depicted in the bottom lines. AU = arbitrary unit; CAI = CSF antibody index; EBNA-1 = EBV nuclear antigen-1; EBV = Epstein-Barr virus; EBV-VCA = EBV viral capsid antigen; HSV = herpes simplex virus; JCV = JC polyomavirus; MRZ = measles, rubella, and zoster antigen; NAT = natalizumab; OCB = oligoclonal band; VZV = varicella zoster virus.](NEURIMMINFL2018018242FF2){#F2}

![Prevalence and loss of intrathecal production of antigen-specific antibodies and OCBs before and during NAT treatment\
(A) Prevalence of patients showing intrathecal production of antibodies to the antigens indicated, before (V0; n = 15, dark gray bars) and after 12 months of NAT treatment (V12; n = 15, light gray bars). (B) Prevalence of patients with positive MRZ reaction, defined as intrathecal production of antibodies against at least 2 of the 3 MRZ antigens (MRZ virus), before (V0, dark gray bars) and after 12 months of NAT treatment (V12, light gray bars) (upper graph) and prevalence of patients with intrathecal production of antibodies against at least 2 of the 20 antigens analyzed in (A), before (V0, dark gray bars) and after 12 months of NAT treatment (V12, light gray bars) (lower graph). (C) Frequency of loss of intrathecal production of antibodies (CAI ≥ 1.5) reactive against JCV (black bar, proportion 3/3) in comparison to the frequency of loss of CAI ≥1.5 specific for all other viral and bacterial antigens tested (white bar, proportion 18/70). (D) Prevalence of patients with positive OCBs as determined by isoelectric focusing before (V0, dark gray bars) and after 12 months of NAT treatment (V12, light gray bars). Statistics: McNemar test (A, B, and D) and Fisher exact test for frequency comparisons (C). In the primary aim, the frequency of loss of CAI ≥1.5 reactive against JCV was compared with that specific for all other antigens, and a probability value of *p* \< 0.05 was considered significant (C). CAI = CSF antibody index; MRZ = measles, rubella, and zoster antigen; NAT = natalizumab; OCB = oligoclonal band.](NEURIMMINFL2018018242FF3){#F3}

Changes of intrathecal production of antigen-specific antibodies during NAT therapy {#s2-3}
-----------------------------------------------------------------------------------

Only the serum levels of rubella virus--reactive antibodies decreased significantly during NAT therapy, but none of the ones reactive to all other antigens (figure e-2 and e-3, [links.lww.com/NXI/A147](http://links.lww.com/NXI/A147) and [links.lww.com/NXI/A148](http://links.lww.com/NXI/A148)). In contrast, NAT therapy reduced CSF levels of antibodies reactive to JCV, BKV, KIV, WUV, measles virus, rubella virus, VZV, mumps virus, EBV-VCA, EBNA-1, influenza A virus, influenza B virus, enterovirus, and tetanus toxoid, but not those reactive to HSV-1, HSV-2, CMV, diphtheria toxoid, *H pylori*, and *C pneumoniae* ([figure 4](#F4){ref-type="fig"} and figure e-2 and e-3, [links.lww.com/NXI/A147](http://links.lww.com/NXI/A147) and [links.lww.com/NXI/A148](http://links.lww.com/NXI/A148)).

![JCV-, BKV-, KIV-, and WUV-reactive antibodies in CSF and serum before (V0) and after 12 months of NAT treatment (V12)\
Serum and CSF levels of antibodies reactive to JCV (A), BKV (B), KIV (C), or WUV (D) are depicted in AUs. Intrathecal production of the respective antibodies is indicated by CSF/serum JCV-, BKV-, KIV-, or WUV-reactive antibody index (CAI~JCV~, CAI~BKV~, CAI~KIV~, and CAI~WUV~). Dashed lines indicate the value changes in the 3 donors with intrathecal production of JCV- and BKV- specific antibodies at V0 and loss thereof at V12 (each n = 15). Continuous horizontal lines indicate COV of seropositivity. Dotted horizontal lines indicate the COV for intrathecal antigen-specific antibody synthesis as defined by CAIspec ≥ 1.5). AU = arbitrary unit; CAI = CSF antibody index; COV = cut-off value; JCV = JC polyomavirus; NAT = natalizumab.](NEURIMMINFL2018018242FF4){#F4}

During NAT therapy, the prevalence of donors producing the respective antigen-specific antibodies reduced by 20.0% in JCV and BKV, respectively, by 13.3% in KIV and influenza B virus, respectively, by 6.7% in 6 of 20 antigens, and stayed unchanged or undetectable in 10 of 20 antigens tested ([figures 2 and 3A](#F2 F3){ref-type="fig"}). Three donors showed intrathecal production of antibodies reactive to both JCV and BKV before NAT therapy, and both reactivities were lost in all 3 donors during NAT treatment, although serum JCV- and BKV-specific antibody responses persisted ([figure 4, A and B](#F4){ref-type="fig"}). In addition, these donors showed a persistent positive MRZ reaction. No cross-reactivity between JCV- and BKV-specific CSF antibodies was detected at baseline (figure e-4, [links.lww.com/NXI/A149](http://links.lww.com/NXI/A149)). MRZ reaction did not change significantly in all other donors during NAT therapy ([figure 3B](#F3){ref-type="fig"}). Intrathecal production of antibodies against ≥2 antigens persisted in all donors ([figure 3B](#F3){ref-type="fig"}). Intrathecal antibody production against JCV was significantly more frequently lost than the intrathecal production of antibodies reactive against all other antigens except JCV (primary aim, *p* = 0.021, [figure 3C](#F3){ref-type="fig"}). The same was true for the combination of JCV and BKV (exploratory aim, *p* = 0.00032) after Bonferroni correction for multiple comparisons (n = 22), but not for any of the other antigens (figure e-5, [links.lww.com/NXI/A150](http://links.lww.com/NXI/A150)).

Changes in OCBs during NAT treatment {#s2-4}
------------------------------------

OCBs were positive in CSF in 93.3% of donors before and in 80.0% of donors during NAT therapy ([figures 2 and 3D](#F2 F3){ref-type="fig"}). Loss of intrathecal OCB production occurred without loss of intrathecal production of antigen-specific antibodies and vice versa (MS13 vs MS02, MS07, MS11, and MS12 in [figure 2](#F2){ref-type="fig"}). OCBs turned positive in 1 patient (MS01) during NAT therapy, which was not accompanied by occurrence of intrathecal production of antigen-specific antibodies ([figure 2](#F2){ref-type="fig"}). Altogether, changes in OCB positivity did not correlate with changes in intrathecal production of antigen-specific antibodies.

Discussion {#s3}
==========

Here, we report a detailed analysis of the influence of NAT therapy on the intrathecal production of antiviral and in particular anti-JCV antibodies in patients with MS and possible implications for the development of NAT-PML. Of note, 50%--70% of patients with MS have been reported to be JCV seropositive.^[@R22]^ Established risk factors for NAT-PML development are increased levels of anti-JCV antibodies in serum, duration of NAT treatment longer than 2 years, and previous long-term immunosuppressive therapies.^[@R22]^ NAT also induces an elevation of B-cell numbers in the peripheral blood, which may serve as a cell pool for JCV infection and dissemination.^[@R23],[@R24]^ NAT-induced upregulation of B-cell transcription factors may activate early JCV gene expression, adding to NAT-PML risk.^[@R25]^ Occurrence of PML during immunomodulatory treatments and in immunodeficiencies that primarily affect B cells indicates the importance of antibodies for controlling JCV.^[@R4],[@R26]^ Recently, we have discovered viral immune escape mechanisms affecting humoral and adaptive JCV-specific immunity.^[@R26],[@R27]^ Patients with MS at onset of NAT-PML showed reduced CSF antibody responses against PML-associated JCV variants, which were closed after immune reconstitution in the CNS for overcoming JCV immune escape.^[@R26],[@R28]^ However, it is not yet well understood why patients with MS with higher serum anti-JCV antibody levels are at a higher risk of NAT-PML^[@R22]^ and whether the affinity of anti-JCV antibodies and/or their ability to recognize and neutralize multiple JCV variants (including PML-associated strains) is deficient in these individuals.^[@R4],[@R26]^ It also remains unclear why NAT therapy is biased to PML and not to any other infectious CNS disease.

By analyzing antibody reactivities against 20 microbial antigens, we demonstrate high interindividual variability in the reactivity of intrathecally produced antibodies against various pathogens in therapy-naive patients with MS. We confirm that intrathecal production of antibodies against ≥2 viral antigens is a frequent feature in therapy-naive patients with MS (found in 80.0%), with MRZ reaction being most prevalent (73.3%).^[@R10],[@R13][@R14][@R15],[@R21]^ As an interesting novel observation, we detected intrathecal production of antibodies in therapy-naive patients with MS against tetanus toxoid (33.3%), JCV (20.0%), BKV (20.0%), KIV (26.7%), and WUV (13.3%). This response may be part of the MS-associated "polyspecific" CSF antibody response similar to a MRZ-like reaction.^[@R10],[@R21]^ What the role of this broad intrathecal humoral immune response in the pathogenesis of MS is and whether it is protective against viral CNS infections are not clear.

In patients with MS, antibody-producing cells (memory B cells, plasmablasts, and plasma cells) frequently circulate between CNS and peripheral blood,^[@R29],[@R30]^ indicating a role of peripheral humoral immunity in shaping the CNS-resident B-cell repertoire. The mechanisms establishing the intrathecal B-cell repertoire are as yet unknown. However, MS-associated CNS inflammation might attract antibody-producing cells by chemokine cues.^[@R31]^ The probability that B cells producing antibodies against a specific pathogen settle to the CNS might be influenced by the frequency of respective CNS homing antibody-producing cells in peripheral blood and their stochastic migration into the CNS. Additional factors may be expression of molecules that are needed for CNS entry and bystander signals for survival.

Of interest, simultaneous intrathecal JCV- and BKV-specific antibody production was found in 20% of patients before NAT therapy, but disappeared during NAT therapy in all of these patients with MS, whereas anti-JCV and -BKV serum antibodies and MRZ reaction and CSF OCBs persisted. Initial reports suggested disappearance of OCBs during NAT therapy in 55%--67% of patients,^[@R9]^ but our data support the persistence of OCBs during NAT therapy and corroborates more recent reports about less prominent changes in OCB prevalence found in 0%--16% of NAT-treated patients.^[@R7],[@R8]^ Methodological differences in OCB detection between the CSF laboratories and differences in MS populations analyzed in the respective studies could account for the discrepant OCB findings seen. Importantly, JCV- and BKV-specific antibody responses were significantly more frequently lost than intrathecal antibody reactivities against other neurotropic viruses and infectious agents, suggesting an antigen-selective loss. BKV shares the highest sequence identity with JCV among human polyomaviruses, and BKV-specific antibodies from healthy donors show frequent cross-reactivity against JCV.^[@R26]^ However, BKV causes nephropathy in up to 10% of kidney transplant recipients and is not considered to be associated with PML, MS, or brain disease.

Differential CNS-migratory properties or requirement of survival factors for JCV- or BKV-specific antibody-producing cells might account for this selective loss. Very Late Antigen (VLA-4) expression allows antibody-producing cells to cross the blood-brain barrier (BBB).^[@R32],[@R33]^ Not only VLA-4 expression levels but also the degree of ligand affinity of VLA-4, which may be modulated by the activation state of the cell, determine adhesion and migratory abilities.^[@R34],[@R35]^ Lower expression or ligand affinity of VLA-4 could be an important factor to hinder JCV- and BKV-specific antibody-producing cells more efficiently from crossing the BBB during NAT therapy than other pathogen-specific B cells.

On CNS entry, plasmablasts that occupy survival niches successfully differentiate into long-lived plasma cells and become immobile.^[@R31]^ In contrast, antibody-producing cells lacking survival cues might eventually undergo apoptosis, and intrathecal antibody secretion might depend on continuous CNS infiltration of peripheral cells. We consider this scenario rather unlikely in the context of JCV- and BKV-specific B cells because the here detected absence of cross-reactivity between JCV- and BKV-specific antibodies in the CNS, which is usually found in sera of healthy donors and patients with MS,^[@R26]^ may indicate affinity maturation of CNS homing, initially cross-reactive B cells to JCV-monospecific and BKV-monospecific cells. Alternatively, intrathecal JCV- and BKV-specific antibody-producing cells might be more dependent on CD4^+^ T-cell help for survival and maturation to long-lived plasma cells than B cells specific for other pathogens. Again, NAT may inhibit CNS entry of antiviral CD4^+^ T cells differentially depending on peripheral precursor frequencies, expression levels of VLA-4, and migratory abilities.^[@R6],[@R34]^

Whereas 20% of therapy-naive patients with MS show intrathecal JCV- and BKV-specific antibody production, NAT therapy appears to abrogate these immune reactions preferentially compared with responses against other neurotropic viruses. The observations of this study not only show the previously known interindividual heterogeneity of the intrathecal polyspecific antiviral humoral immune reactions in patients with MS but also indicate intraindividual heterogeneity in the persistence of intrathecal antigen-specific antibody reactivities with some being more stable and persistent (e.g., MRZ reaction) than others (intrathecal JCV-specific antibody synthesis). Assuming that intrathecally produced anti-JCV antibodies are protective, their loss during NAT treatment could result in higher risk for PML development. Limitations of our study are the small cohort size and short observation period, respectively. Larger studies are needed to define how NAT-induced loss of intrathecal JCV-specific antibody production influences PML risk.
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:   EBV viral capsid antigen

HSV

:   herpes simplex virus

JCV

:   JC polyomavirus

MRZ reaction

:   measles, rubella, and zoster antigens

NAT

:   natalizumab

OCB

:   oligoclonal band

OD

:   optical density

PML

:   progressive multifocal leukoencephalopathy

RRMS

:   relapsing-remitting MS

VZV

:   varicella zoster virus
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